News and Events – COD Research

WDSC-Web-Upcoming

2 days ago

WDSC upcoming

Posted by cppl_codresearch_2022

Bio-2024-Attendee-Web-01_ Upcoming

Bio 2024 upcoming

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

DIA 2023 in Boston, Massachusetts

CODE Exhibiting at BIO 2024

DCAT 2023 in New York City

Scope 2023 in Orlando, Florida

Events

2 years ago

Pharmacovigilance System guideline of South Africa – A high level glance

Events

1 year ago

COD research is delighted to present on “Career Opportunities in Pharmacovigilance”

Events

1 year ago

An insightful session on “ISO: 14155- Introduction to Clinical Investigation for Medical Devices” by Dr. Ashok Thakkar

Events

1 year ago

38th International Society for Pharmacoepidemiology (ICPE)

Events

1 year ago

We are delighted to welcome Mohit Kapoor as Director – Project Management and Operations Strategy

Events

1 year ago

We are the silver sponsor at WDSC-2022

Events

1 year ago

Dr Jay Dave is among the selected speakers to give a presentation during the event.

Events

1 year ago

Experts at our Booth # 42 are awaiting your presence to unlock your Drug Safety Challenges and enhance compliance.

Events

1 year ago

CPhI Frankfurt is calling!

Events

1 year ago

COD Research USA INC is attending World Drug Safety Congress – 2022, Boston.

Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
Source: EMA Published on 2024-05-08
CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
Source: EMA Published on 2024-05-08
Timetable: Post-authorisation safety study (PASS) protocols and final results
Source: EMA Published on 2024-05-08
Timetable: Initial (Full) marketing authorisation application - ATMP
Source: EMA Published on 2024-05-08
Organisation chart: Advisory functions
Source: EMA Published on 2024-05-07
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024
Source: EMA Published on 2024-05-07
EMA closed 9-10 May
Source: EMA Published on 2024-05-07
Information session on Call for Proposals "EU 4 AMA: leveraging European expertise for medicines regulation in Africa", Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 May 2024, 10:00 (CEST) to 22 May 2024, 11:00 (CEST)
Source: EMA Published on 2024-05-07
PRIME: priority medicines
Source: EMA Published on 2024-05-07
List of medicines currently in PRIME scheme
Source: EMA Published on 2024-05-07
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Status: Authorised
Source: EMA Published on 2024-05-07
One Health: a joint framework for action published by five EU agencies
Source: EMA Published on 2024-05-07
Product Management Service (PMS) Info-Day, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 April 2024, 09:15 (CEST) to 16 April 2024, 17:30 (CEST)
Source: EMA Published on 2024-05-07
COVID-19 vaccines: key facts
Source: EMA Published on 2024-05-07
Record of data processing activity relating to Security Access Control System (public)
Source: EMA Published on 2024-05-06

Withdrawn | Expired Guidances
Source: FDA Published on 2024-05-09
Drug Trials Snapshots: RYSTIGGO
Source: FDA Published on 2024-05-09
OSIS Workshop: CDER Bioavailability/Bioequivalence Study Sites and Inspections of Good Laboratory Practice - 06/13/2024
Source: FDA Published on 2024-05-09
Should You Put Sunscreen on Infants? Not Usually
Source: FDA Published on 2024-05-09
Tips to Stay Safe in the Sun: From Sunscreen to Sunglasses
Source: FDA Published on 2024-05-09
Expanded Access (Compassionate Use) Submission Data Archive: CDRH
Source: FDA Published on 2024-05-09
Switching Between Biosimilars and Their Reference Counterparts with Dr. Sarah Yim
Source: FDA Published on 2024-05-08
Drug Trials Snapshots: ZELSUVMI
Source: FDA Published on 2024-05-08
Expanded Access (Compassionate Use) Submission Data Archive: CDER and CBER
Source: FDA Published on 2024-05-08
OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2024 User Fees and Registration - 06/18/2024
Source: FDA Published on 2024-05-08
Online Verification of Electronic Certificates of Pharmaceutical Product
Source: FDA Published on 2024-05-08
Novel Drug Approvals for 2024
Source: FDA Published on 2024-05-08
GDUFA I
Source: FDA Published on 2024-05-08
CDERLearn
Source: FDA Published on 2024-05-08
CDER Center for Clinical Trial Innovation (C3TI)
Source: FDA Published on 2024-05-08

Field Safety Notices: 22 to 26 April 2024
Source: MHRA Published on 2024-05-01
Field Safety Notices: 15 to 19 April 2024
Source: MHRA Published on 2024-04-25
Class 3 Medicines Recall: Neon Healthcare Ltd, Suprefact 1 mg/ml solution for injection (Cheplapharm – Canadian Livery), EL(24)A/14
Source: MHRA Published on 2024-04-23
Symbios ORIGIN® Posterior Stabilised Patient-Matched Total Knee Replacement Device: Risk of Early Revision, DSI/2024/005
Source: MHRA Published on 2024-04-23
Class 3 Medicines Recall: A. Menarini Farmaceutica Internazionale Srl, Invokana 300mg tablets (Northern Ireland only), EL(24)A/13
Source: MHRA Published on 2024-04-16
Field Safety Notices: 8 to 12 April 2024
Source: MHRA Published on 2024-04-15
Field Safety Notices: 2 to 6 October 2023
Source: MHRA Published on 2024-04-12
Class 3 Medicines Recall: Accord-UK Ltd, Co-Codamol 8/500mg Effervescent Tablets (Key Pharmaceuticals Livery), EL (24)A/12
Source: MHRA Published on 2024-04-10
Field Safety Notices: 1 to 5 April 2024
Source: MHRA Published on 2024-04-09
0.9% Sodium Chloride Solutions for Irrigation, Inhalation, and Eyewash: recall from manufacturer Legency Remedies, DSI/2024/004
Source: MHRA Published on 2024-04-04
National Patient Safety Alert: Reducing risks for transfusion-associated circulatory overload (NatPSA/2024/004/MHRA)
Source: MHRA Published on 2024-04-04
Class 3 Medicines Recall: Bristol-Myers Squibb Pharmaceuticals Limited, OPDIVO 10 mg/mL concentrate for solution for infusion (nivolumab), EL(24)A/11
Source: MHRA Published on 2024-04-04
Field Safety Notices: 25 to 29 March 2024
Source: MHRA Published on 2024-04-03
Field Safety Notices: 18 to 22 March 2024
Source: MHRA Published on 2024-03-27
Field Safety Notices: 11 to 15 March 2024
Source: MHRA Published on 2024-03-25

FDA

Withdrawn | Expired Guidances
Source: FDA Published on 2024-05-09
Drug Trials Snapshots: RYSTIGGO
Source: FDA Published on 2024-05-09
OSIS Workshop: CDER Bioavailability/Bioequivalence Study Sites and Inspections of Good Laboratory Practice - 06/13/2024
Source: FDA Published on 2024-05-09
Should You Put Sunscreen on Infants? Not Usually
Source: FDA Published on 2024-05-09
Tips to Stay Safe in the Sun: From Sunscreen to Sunglasses
Source: FDA Published on 2024-05-09
Expanded Access (Compassionate Use) Submission Data Archive: CDRH
Source: FDA Published on 2024-05-09
Switching Between Biosimilars and Their Reference Counterparts with Dr. Sarah Yim
Source: FDA Published on 2024-05-08
Drug Trials Snapshots: ZELSUVMI
Source: FDA Published on 2024-05-08
Expanded Access (Compassionate Use) Submission Data Archive: CDER and CBER
Source: FDA Published on 2024-05-08
OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2024 User Fees and Registration - 06/18/2024
Source: FDA Published on 2024-05-08
Online Verification of Electronic Certificates of Pharmaceutical Product
Source: FDA Published on 2024-05-08
Novel Drug Approvals for 2024
Source: FDA Published on 2024-05-08
GDUFA I
Source: FDA Published on 2024-05-08
CDERLearn
Source: FDA Published on 2024-05-08
CDER Center for Clinical Trial Innovation (C3TI)
Source: FDA Published on 2024-05-08

Biosimilar-main-slider

Upcoming Events

News &
Events

Explore

Drag